ret de kontrollerede forsøg (I- IX, CLASSIC I, GAIN og CHARM) (beskrevet i punkt 5. 1), som omfatter 3271 patienter, der fik Trudexa, og 1809 patienter, der fik enten placebo eller aktiv kontrol i den kontrollerede behandlingsperiode.
The proportion of patients who discontinued treatment due to adverse events during the double-blind, controlled portion of Studies I− IX, CLASSIC I, GAIN and CHARM was 5.7% for patients taking